Platform Trials to Expedite Drug Development in Alzheimer’s Disease: A Report from the EU/US CTAD Task Force

A diverse range of platforms has been established to increase the efficiency and speed of clinical trials for Alzheimer’s disease (AD). These platforms enable parallel assessment of multiple therapeutics, treatment regimens, or participant groups; use uniform protocols and outcome measures; and may...

Descripción completa

Detalles Bibliográficos
Autores principales: Aisen, P. S., Bateman, R. J., Carrillo, M., Doody, R., Johnson, K., Sims, J. R., Sperling, R., Vellas, B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
CTAD Task Force Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8136263/
https://www.ncbi.nlm.nih.gov/pubmed/34101788
http://dx.doi.org/10.14283/jpad.2021.21

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8136263/
https://www.ncbi.nlm.nih.gov/pubmed/34101788
http://dx.doi.org/10.14283/jpad.2021.21

Ejemplares similares